Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial

When the Global Coalition for Adaptive Research brought the PI3K inhibitor paxalisib into its platform trial for glioblastoma in early 2021, the drug’s developer — Australia’s Kazia Therapeutics — was upbeat about how success in the trial, dubbed GBM AGILE, may speed up the process of finding effective therapies and “pave the way to providing a new treatment in this disease.”